APOC3
ENSG00000110245
Target class
Unclassified protein
Chromosome
11
- Chemical probe available
- No
- Target name
- APOC3
- Gene name
- Apolipoprotein C3
- Gene symbol
- APOC3
- Protein name
- Apolipoprotein C-III (Apo-CIII) (ApoC-III) (Apolipoprotein C3)
- Apo-CIII
- ApoC-III
- APOCIII
- Apo-C3
- ApoC-3
- Gene biotype
- Protein coding
- Gene family
- Apolipoproteins
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 5
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 7,599.74
- Tissue specificity (Gini)
- 0.98
- Tissue specificity (tau)
- 1
- KEGG gene identifiers
- hsa:345
- Protein interaction confidence
- 0.861947
- Protein interaction partners
- 57
- R-HSA-8963888
- R-HSA-8963901
- R-HSA-8964058
- R-HSA-975634
- End position
- 116833343
- Start position
- 116827019
- Chromosome
- 11
- Strand
- Forward
- Secreted .
- Cell Junctions
- Nucleoli
- Nucleoplasm
- PubMed 18201179
- PubMed 22510806
- Tissue specificity (tau)
- 0.999705
- Expression inequality (Gini)
- 0.980072
Expression in transcripts per million
- Liver
- 7,599.74
- Small Intestine - Terminal Ileum
- 105.64
- Kidney - Cortex
- 1.4
- Kidney - Medulla
- 1.07
- Testis
- 1.02
Expression in transcripts per million
- Liver7,599.74
- Small Intestine - Terminal Ileum105.64
- Kidney - Cortex1.4
- Kidney - Medulla1.07
- Testis1.02
- Whole Blood0.59
- Spleen0.56
- Cervix - Ectocervix0.45
- Fallopian Tube0.42
- Lung0.4
- Uterus0.39
- Pituitary0.37
- Cells - Cultured fibroblasts0.37
- Brain - Cerebellum0.37
- Stomach0.36
- Ovary0.35
- Pancreas0.34
- Colon - Transverse0.31
- Adipose - Visceral (Omentum)0.3
- Esophagus - Mucosa0.3
- Prostate0.29
- Artery - Coronary0.26
- Adrenal Gland0.25
- Thyroid0.24
- Vagina0.23
And 29 more, listed on the interactive page.
- GO:0006641
- GO:0006869
- GO:0007186
- GO:0010897
- GO:0010903
- GO:0010916
- GO:0010987
- GO:0010989
- GO:0019433
- GO:0032489
- GO:0033344
- GO:0033700
- GO:0034375
- GO:0034379
- GO:0034382
- GO:0042632
- GO:0043691
- GO:0045717
- GO:0045833
- GO:0048261
- GO:0050995
- GO:0060621
- GO:0070328
- GO:0005576
- GO:0005769
- GO:0034361
- GO:0034363
- GO:0034366
- GO:0042627
- GO:0070062
- GO:0005515
- GO:0005543
- GO:0015485
- GO:0055102
- GO:0070653
Related records
Trials (21)
- A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia
- A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
- A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia
- A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia
- A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
- A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
- A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers
- CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
- Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
- Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
- Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
- Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides
- Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)
- The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
- The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
- The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
- The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
Drugs (3)
- Olezarsen Apolipoprotein C-III mRNA antisense inhibitor
- Volanesorsen Apolipoprotein C-III mRNA 3'UTR antisense inhibitor
- Volanesorsen sodium Apolipoprotein C-III mRNA 3'UTR antisense inhibitor